The current role of mitoxantrone in the treatment of multiple sclerosis

Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study

(2013) Victor M Rivera et al.   BMC Neurology

Incidence and prevalence of multiple sclerosis in Europe: a systematic review

(2013) Elaine Kingwell et al.   BMC Neurology

Requirement for safety monitoring for approved multiple sclerosis therapies: an overview

(2013) P. S. Rommer et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Induction Therapy for Patients with Multiple Sclerosis: Why? When? How?

(2013) Gilles Edan et al.   CNS DRUGS

Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance

(2013) Ellen Lu et al.   Expert Review of Neurotherapeutics

Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis

(2013) Markus Axelsson et al.   Multiple Sclerosis Journal

Mitoxantrone-related acute leukemia in MS: An open or closed book?

(2013) A. Chan et al.   NEUROLOGY

Placebo Cohorts in Phase-3 MS Treatment Trials – Predictors for On-Trial Disease Activity 1990-2010 Based on a Meta-Analysis and Individual Case Data

(2012) Jan-Patrick Stellmann et al.   PLoS One

Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany

(2012) Anke Stroet et al.   Therapeutic Advances in Neurological Disorders

Mitoxantrone exerts both cytotoxic and immunoregulatory effects on activated microglial cells

(2011) Jun-Min Li et al.   IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY

Managing MS in a changing treatment landscape

(2011) Martin Duddy et al.   JOURNAL OF NEUROLOGY

Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial

(2011) G. Edan et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis

(2011) Per Soelberg Sørensen   JOURNAL OF THE NEUROLOGICAL SCIENCES

Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study

(2011) E Le Page et al.   Multiple Sclerosis Journal

Risk of acute promyelocytic leukemia in multiple sclerosis: Coding variants of DNA repair genes

(2011) S. K. Hasan et al.   NEUROLOGY

Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone

(2011) V. Martinelli et al.   NEUROLOGY

Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis

(2010) E. Ammatuna et al.   HAEMATOLOGICA

Comparative study of mitoxantrone efficacy profile in patients with relapsing—remitting and secondary progressive multiple sclerosis

(2010) Federica Esposito et al.   Multiple Sclerosis Journal

SEVERE CARDIAC FAILURE IN A PATIENT WITH MULTIPLE SCLEROSIS FOLLOWING LOW-DOSE MITOXANTRONE TREATMENT

(2010) J. Killestein et al.   NEUROLOGY

Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS

(2010) E. Kingwell et al.   NEUROLOGY

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

(2010) J. J. Marriott et al.   NEUROLOGY

The Misperception That Clinical Trial Data Reflect Long-term Drug Safety

(2009) Tamar Nijsten et al.   ARCHIVES OF DERMATOLOGY

ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis

(2009) S. Cotte et al.   BRAIN

Concepts of induction and escalation therapy in multiple sclerosis

(2009) Peter Rieckmann   JOURNAL OF THE NEUROLOGICAL SCIENCES

The Will Rogers phenomenon: the effect of different diagnostic criteria

(2009) Maria Pia Sormani   JOURNAL OF THE NEUROLOGICAL SCIENCES

Use of arsenic trioxide in secondary acute promyelocytic leukemia developing after treatment of multiple sclerosis with mitoxantrone

(2009) Emanuele Ammatuna et al.   LEUKEMIA & LYMPHOMA

Mitoxantrone and cytotoxic drugs' mechanisms of action

(2009) T. Vollmer et al.   NEUROLOGY

Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis

(2008) S. K. Hasan et al.   BLOOD

Assessment of Mitoxantrone-Induced Cardiotoxicity in Patients with Multiple Sclerosis: A Tissue Doppler Echocardiographic Analysis

(2008) Paolo Pattoneri et al.   ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES

Basic and escalating immunomodulatory treatments in multiple sclerosis: Current therapeutic recommendations

(2008) et al.   JOURNAL OF NEUROLOGY

Multiple sclerosis

(2008) Alastair Compston et al.   LANCET

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis

(2008) T Vollmer et al.   Multiple Sclerosis Journal

Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study

(2008) E Cocco et al.   Multiple Sclerosis Journal

Temporal trends in the incidence of multiple sclerosis: A systematic review

(2008) A. Alonso et al.   NEUROLOGY

Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients

(2007) E. Le Page et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY